Dual JAK and ROCK inhibition with CPL’116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo controlled, phase 2 trial
Lancet Rheumatol 2025;25:00060-8 doi: 10.1016/S2665-9913(25)00060-8
Wieczorek et al. present the first evidence supporting the use of a dual JAK and ROCK inhibitor as a potential treatment option for patients with RA who have inadequate response to MTX. Wieczorek et al. conducted a randomised, Phase 2 study of CPL’116 in patients with RA with inadequate response to MTX, to evaluate dose-dependent effects on disease control and pharmacokinetics, and its effect on laboratory abnormalities among other safety assessments.
CPL’116 240mg improved DAS28-CRP at Week 12, with a high remission rate observed. CPL’116 appeared to effectively target the JAK pathway, alleviating RA symptoms while avoiding the side-effects typically associated with JAKis. CPL’116 was generally well-tolerated and was not associated with lipid abnormalities or creatinine kinase increase.
